NICE TA657: for previously treated multiple myeloma (replaces NICE TA457). (Decision date - December 2020).
NICE TA695: Carfilzomib with dexamethasone and
lenalidomide for previously treated multiple myeloma. (Decision date - May 2021).
Do Not Prescribe (DNP):
NICE TA841: Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma. Terminated appraisal. (Decision date - December 2022)
NHS England drug. To be used in line with NHSE commissioning intentions.
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
8. NHS England commissioned – to be used in line with NHSE commissioning intentions
